More
8 April 2024
Cancer screening metrics: effective evaluation to balance benefits and harms
A new study led by researchers at the International Agency for Research on Cancer (IARC) and published today in the Journal of the American Medical Association assesses whether the incidence of late-stage cancer could be a suitable alternative end-point in randomized clinical trials of cancer screening, in place of cancer-specific mortality, the gold-standard end-point.
Feng X, Zahed H, Onwuka J, Callister ME, Johansson M, Etzioni R, et al.
Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis
JAMA. Published online 7 April 2024
https://doi.org/10.1001/jama.2024.5814
Other news
Cervical Cancer Elimination Day of Action 2024: celebrating front-line workers and transforming global commitments into life-saving actions
The Cervical Cancer Elimination Day of Action on 17 November 2024 marks the fourth year of a glob...
18.11.2024
Read more
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination
Scientists from the International Agency for Research on Cancer (IARC) and partner institutions h...
12.11.2024
Read more
Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings
In a new paper, researchers from the International Agency for Research on Cancer (IARC) show that...
12.11.2024
Read more